
April 13, 2022
Levitee Labs Inc. (CSE: LVT) (OTC: LVTTF) (FSE: 7H7) (the "Company" or "Levitee") announces that it has issued an aggregate 5,450,000 common shares in the capital of the Company (the "Debt Shares"), at a deemed price of $0.075 per Debt Share, to settle a bona fide debt in the amount of $408,750 (the "Debt Settlement") owed by the Company's wholly-owned subsidiary, Levitee Real Estate Inc. (the "Subsidiary"), to an arm-length company (the "Creditor") pursuant to the terms of a debt settlement agreement among the parties, dated February 28, 2022.
All securities issued in connection with the Debt Settlement are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation. Closing of the Debt Settlement is subject to a number of conditions, including receipt of all necessary regulatory approvals.
About Levitee Labs
Levitee is establishing itself as a leader in the integrative wellness space. Through integrating evidence-based complementary medicines into the traditional infrastructure of mental health and addiction services, Levitee aims to transform mental health and addiction treatments.
The Company's current portfolio of assets includes: Levitee Clinics(TM), a group of five operating addiction and pain treatment clinics in Alberta; Levitee Pharmacies(TM), three pharmacies operating in Alberta specialized in filling prescriptions for patients with substance use disorders, mental health conditions, and chronic pain; BlockMD, the first technology company in Alberta to receive provincial approval for electronic-prescriptions in the addiction treatment space; and Earth Circle Organics, a direct-to-consumer and wholesaler of supplements and superfood products with 180+ SKUs in its product lineup across three brands.
Further information about Levitee is available on its website at www.leviteelabs.com.
Investor and Corporate Communications:
Philip van den Berg
hello@leviteelabs.com
Media Contact:
Olivia Belcher-Coward, Marketing & Communications Manager
+1 604-789-9973
media@leviteelabs.com
Forward-Looking Statements
This news release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance, or achievements that Levitee anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Such information may involve, but is not limited to, statements respecting Levitee's business plans and proposed products, and the benefits derived from mushroom-infused products; the acquisitive growth potential of Levitee once acquisitions are completed; the expectation that Levitee will continue to execute its accretive acquisition program, and the contribution of such program to Levitee's future growth potential; and Levitee's objective to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results "may", "could", "would", "might" or "will" (or other variations of the forgoing) be taken, occur, be achieved, or come to pass. These statements and other forward-looking information are based on assumptions made by Levitee based on currently available competitive, financial and economic data and operating plans, strategies or beliefs as of the date of this news release as well as management's current expectations or beliefs regarding future growth, results of operations, future capital (including the amount, nature and sources of funding thereof) and expenditures. These assumptions may also be based on information obtained from third-party industry analysts and other third-party sources. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Levitee as of the date such statements are made, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to risks associated with the following: Levitee's limited history of operations; ability to secure additional financing; negative cash flow from operating activities since inception; regulatory requirements; changes in consumer preferences; supply of raw materials; reliance on a limited number of products; brand awareness; the ability to develop, market and produce new products; dependence on certain key senior managers; reliance on third parties for manufacturing and packaging; potential product liability claims and product recalls; and significant competition. For additional information regarding these risks, please see the risk factors identified and reported in Levitee's public filings under its SEDAR profile at www.sedar.com. Any and all forward-looking information contained in this press release is expressly qualified by this cautionary statement. Readers are cautioned not to place undue reliance on forward-looking statements or information. The forward-looking information is made as of the date of this news release, and Levitee assumes no obligation to publicly update or revise such forward-looking information, except as required by applicable securities laws. The Canadian Securities Exchange has neither approved nor disapproved of the contents of this press release and accepts no responsibility for the adequacy or accuracy hereof.
LVT:CC
The Conversation (0)
21 July 2021
Levitee Labs
Transforming the Traditional Landscape of Mental Health, Addiction Treatment and Pain Management Treatment Across Multiple Verticals
01 February 2022
Levitee Labs Announces Philip Van Den Berg to Join as Interim CEO and the Board of Directors and Close First Tranche of Private Placement for $1.5 Million
Levitee Labs Inc. (CSE: LVT) (OTC: LVTTF) (FSE: 7H7) (the " Company " or " Levitee ") is pleased to announce the Company has appointed Philip van den Berg as Chief Executive Officer and to the Board of Directors replacing Mr. Pouya Farmand who will be moving to the position of founder. In his... Keep Reading...
18 January 2022
Levitee Labs Announces Non-Brokered Private Placement of up to $3,000,000
Offering is priced at $0.20 per offered unit, with a full warrant at $0.40 for 24 months Proceeds to be used for organic and inorganic growth initiatives and refocusing the company on clinical healthcare with a focus on addiction services Levitee Labs Inc. (CSE: LVT) (OTC: LVTTF) (FSE: 7H7) (the... Keep Reading...
12 January 2022
Levitee Labs Signs Retail Distribution Agreement with Body Energy Club for MONKE Nutraceuticals
In business for 20 years, Body Energy Club is the leading health supplement and vitamin retailer in Western Canada, with additional locations established in Hollywood, California in 2017 Levitee Nutraceuticals, a division of Levitee Labs , brand MONKE Nutraceuticals ™ currently has two health... Keep Reading...
10 January 2022
Levitee Labs Partners with Canntab Therapeutics to Provide Alternatives to Opioids
The agreement is anticipated to contribute to correcting the opioid crisis in Canada and serve as a foundation for both companies to potentially expand into new verticals in the future Levitee Labs and Canntab Therapeutics have executed a services agreement resulting in Levitee Labs informing... Keep Reading...
06 January 2022
CORRECTION - Levitee Labs Announces Medical Advisory Board
In a press release issued earlier today under the same headline by Levitee Labs Inc. (CSE: LVT) (OTC: LVTTF) (FSE: 7H7), please be advised that the Levitee Labs Medical Advisory Board does not include Dr. Pamela J. Simms-Mackey, MD, FAAP, as previously stated. The corrected release follows:... Keep Reading...
16 September
Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto
lobe sciences ltd. (CSE: LOBE,OTC:LOBEF) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming... Keep Reading...
30 July
Psychedelics Market Update: H1 2025 in Review
The market for psychedelic drugs is emerging as a strategic investment opportunity in healthcare, with forecasts generally placing its value at around US$6.4 billion in 2025. This burgeoning sector is set for robust, double-digit compound annual growth, significantly driven by North America,... Keep Reading...
08 May
US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025
When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry. However, the sector is seeing a resurgence of optimism in 2025 on the back of various... Keep Reading...
03 March
Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia
Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia.... Keep Reading...
18 February
Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025
Compass management will host a conference call at 8:00 am ET (1:00pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth... Keep Reading...
23 January
Psychedelics Market Forecast: Top Trends for Psychedelics in 2025
The psychedelics investment landscape enters 2025 on a complex path marked by both progress and setbacks. While the US Food and Drug Association (FDA) continues to support research into the therapeutic potential of psychedelics, translating promising findings into approved treatments and... Keep Reading...
Latest News
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00